Movement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally

Market Focus10:32

On September 30, SKB BIO rose 3.42% in regular trading, trading at HK$489.6/share, with turnover of approximately HK$104 million.

On the news front, the company recently announced that its independently developed TROP2 ADC sac-TMT (sacituzumab tirumotecan) had multiple Phase III clinical studies selected as Late-Breaking Abstracts (LBA) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October, to be presented as oral reports — a key near-term catalyst. This follows a strong first-half performance, during which product sales surged 112% year-over-year to RMB 657 million, driving the company to its first-ever half-year profit of RMB 388 million. Multiple brokerages including UBS, CLSA, and Bank of America have raised their target prices to a range of HK$626–678, all maintaining buy ratings.

Meanwhile, the broader biotech sector rallied, with CanSinoBIO up 17.75%, BeiGene up 2.75%, and Innovent Bio up 2.03%, providing additional sector-level momentum. Separately, Oriental Securities increased its stake to 5.0% on September 22, signaling continued institutional interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163597789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163597789","market":"us","top_or_hot":-1,"title":"Movement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally","media":"Market Focus","content":"<p><p>On September 30, SKB BIO rose 3.42% in regular trading, trading at HK$489.6/share, with turnover of approximately HK$104 million.</p><p>On the news front, the company recently announced that its independently developed TROP2 ADC sac-TMT (sacituzumab tirumotecan) had multiple Phase III clinical studies selected as Late-Breaking Abstracts (LBA) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October, to be presented as oral reports — a key near-term catalyst. This follows a strong first-half performance, during which product sales surged 112% year-over-year to RMB 657 million, driving the company to its first-ever half-year profit of RMB 388 million. Multiple brokerages including UBS, CLSA, and Bank of America have raised their target prices to a range of HK$626–678, all maintaining buy ratings.</p><p>Meanwhile, the broader biotech sector rallied, with CanSinoBIO up 17.75%, BeiGene up 2.75%, and Innovent Bio up 2.03%, providing additional sector-level momentum. Separately, Oriental Securities increased its stake to 5.0% on September 22, signaling continued institutional interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SKB BIO Rises 3.42% in Regular Trading, TROP2 ADC Sac-TMT Studies Selected as LBA at ESMO Conference Amid Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, SKB BIO rose 3.42% in regular trading, trading at HK$489.6/share, with turnover of approximately HK$104 million.</p><p>On the news front, the company recently announced that its independently developed TROP2 ADC sac-TMT (sacituzumab tirumotecan) had multiple Phase III clinical studies selected as Late-Breaking Abstracts (LBA) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October, to be presented as oral reports — a key near-term catalyst. This follows a strong first-half performance, during which product sales surged 112% year-over-year to RMB 657 million, driving the company to its first-ever half-year profit of RMB 388 million. Multiple brokerages including UBS, CLSA, and Bank of America have raised their target prices to a range of HK$626–678, all maintaining buy ratings.</p><p>Meanwhile, the broader biotech sector rallied, with CanSinoBIO up 17.75%, BeiGene up 2.75%, and Innovent Bio up 2.03%, providing additional sector-level momentum. Separately, Oriental Securities increased its stake to 5.0% on September 22, signaling continued institutional interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1163597789","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163597789","pubTimestamp":1790735543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, SKB BIO rose 3.42% in regular trading, trading at HK$489.6/share, with turnover of approximately HK$104 million.On the news front, the company recently announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势警报|SKB BIO 常规交易上涨 3.42%，TROP2 ADC Sac-TMT 研究在行业反弹中被选为 ESMO 会议上的 LBA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On September 30, SKB BIO rose 3.42% in regular trading, trading at HK$489.6/share, with turnover of approximately HK$104 million.On the news front, the company recently announced that its independently developed TROP2 ADC sac-TMT (sacituzumab tirumotecan) had multiple Phase III clinical studies selected as Late-Breaking Abstracts (LBA) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October, to be presented as oral reports — a key near-term catalyst. This follows a strong first-half performance, during which product sales surged 112% year-over-year to RMB 657 million, driving the company to its first-ever half-year profit of RMB 388 million. Multiple brokerages including UBS, CLSA, and Bank of America have raised their target prices to a range of HK$626–678, all maintaining buy ratings.Meanwhile, the broader biotech sector rallied, with CanSinoBIO up 17.75%, BeiGene up 2.75%, and Innovent Bio up 2.03%, providing additional sector-level momentum. Separately, Oriental Securities increased its stake to 5.0% on September 22, signaling continued institutional interest.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163597789","isCrawlerRequest":true}